Abstract
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::JAKMIP1 fusion. CT images of target lesions in the lung are shown at baseline, first partial response at 8 weeks, and at 15.7 weeks as a confirmatory PR.